NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test
Rhea-AI Summary
NexTel Medical Corp (OTCPK: MAJI) announced the start of distribution of NANOG DNA cancer screening test kits the week of April 7, 2026 to collect control samples and validate against 100 dedicated test samples. The company said it holds a patent granted from a limited sample set and is expanding testing to broader cancer types.
The non-invasive assay uses a 2 ml saliva sample and standard PCR to measure exosomal NANOG DNA, aiming for universal multi-cancer screening with rapid, scalable processing as the firm advances toward commercialization.
Positive
- Distribution started of test kits the week of April 7, 2026
- Patent granted for the NANOG DNA test (based on initial sample set)
- Non-invasive 2 ml saliva sample and standard PCR processing for scalability
- Expanding testing protocols to include a broader range of cancer types
Negative
- Initial patent and validation were based on a limited sample set
- Planned validation benchmark is only 100 dedicated test samples at this phase
News Market Reaction – MAJI
In the Apr 7 session, MAJI declined 11.00%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp f/k/a Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is proud to announce the commencement of the first critical phase in bringing its revolutionary cancer screening test to the global market.
NexTel will begin the distribution of test kits this week to initiate the collection of essential control samples. These samples serve as the foundational benchmark for validation against 100 dedicated test samples. While the initial patent was granted based on a limited sample set, NexTel is now aggressively expanding its testing protocols to include a broader range of cancer types. This scaling of sample size and diversity is a vital step in confirming the universal efficacy of the test as the company moves toward full-scale commercialization.
A New Frontier in Early Detection: The NANOG DNA Advantage
The core of NexTel’s diagnostic portfolio is the proprietary NANOG DNA cancer screening test. Designed as a non-invasive, high-precision tool, the test is engineered to detect a wide spectrum of malignancies, including the "silent killers"—highly aggressive cancers that are notoriously difficult to identify until they reach advanced stages.
The NANOG DNA assay offers a transformative shift in the liquid biopsy landscape:
- Universal Multi-Cancer Screening: A single, comprehensive tool designed to identify various cancer types simultaneously, removing the need for multiple, invasive procedures.
- Unrivaled Sensitivity: By measuring Exosomal NANOG DNA, a potent and reliable biomarker, the test remains unaffected by external medications or co-existing health conditions.
- Seamless Integration: Requiring only a 2 ml saliva sample, the test utilizes standard PCR processing. This enables rapid, scalable results and removes the traditional barriers to cost and time associated with early detection.
Executive Commentary
“This milestone represents an incredibly exciting leap forward in our mission to democratize cancer screening,” said Matt Dwyer, President of NexTel Medical Corp. “Cancer is a diagnosis that has touched every one of us. We know that early detection is the absolute key to survival, yet the current hurdles of cost and accessibility keep far too many people from getting the answers they need. Our goal is to offer an affordable solution so simple and accessible that it changes the diagnostic landscape forever. This test is so efficient that a participant could purchase the kit, walk to their car, and complete the screening before they even buckle their seatbelt. We are thrilled to be this much closer to putting that power in the hands of the public.”
About NexTel Medical Corp: NexTel Medical Corp (OTCPK: MAJI) is a pioneering biotechnology company at the forefront of exosome research and diagnostic innovation. Dedicated to developing next-generation delivery systems for both therapeutic and diagnostic applications, the Company focuses on creating non-invasive screening tools and scalable solutions for the future of personalized medicine. Through its expanding telehealth division, NexTel aims to bridge the gap between complex clinical innovation and direct patient access, providing advanced technologies that improve outcomes and streamline the modern healthcare experience.
Forward-Looking Statements: This press release contains forward-looking statements regarding the development and commercialization of NexTel Medical Corp’s products. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. NexTel Medical Corp's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of NexTel Medical Corp., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
NexTel Medical Corp.
www.nextelmedical.com
X: @NexTelMedical
Investor Relations
ir@exousiapro.com
